Overcoming Drug Resistance of Cancer Cells by Targeting the FGF1/FGFR1 Axis with Honokiol or FGF Ligand Trap

Overview

Journal Front Pharmacol

Date 2024 Sep 27

PMID 39329123

Authors

Jakub Szymczyk

Martyna Sochacka

Martyna Biadun

Katarzyna Dominika Sluzalska

Danuta Witkowska

Malgorzata Zakrzewska

Affiliations

Soon will be listed here.

Abstract

Background: Chemoresistance of cancer cells, resulting from various mechanisms, is a significant obstacle to the effectiveness of modern cancer therapies. Targeting fibroblast growth factors (FGFs) and their receptors (FGFRs) is becoming crucial, as their high activity significantly contributes to cancer development and progression by driving cell proliferation and activating signaling pathways that enhance drug resistance.

Methods: We investigated the potential of honokiol and FGF ligand trap in blocking the FGF1/FGFR1 axis to counteract drug resistance. Using PEAQ-ITC, we verified direct interaction of honokiol with the FGFR1 kinase domain. We then demonstrated the effect of FGF1/FGFR1 inhibition on taltobulin resistance in cells expressing FGFR1. Finally, we generated drug-resistant clones by prolonged exposure of cells with negligible FGFR levels to taltobulin alone, taltobulin and honokiol, or taltobulin and FGF ligand trap.

Results: We demonstrated for the first time a direct interaction of honokiol with the FGFR1 kinase domain, resulting in inhibition of downstream signaling pathways. We revealed that both honokiol and FGF ligand trap prevent FGF1-dependent protection against taltobulin in cancer cells expressing FGFR1. In addition, we showed that cells obtained by long-term exposure to taltobulin are resistant to both taltobulin and other microtubule-targeting drugs, and exhibit elevated levels of FGFR1 and cyclin D. We also found that the presence of FGF-ligand trap prevents the development of long-term resistance to taltobulin.

Conclusion: Our results shed light on how blocking the FGF1/FGFR1 axis by honokiol and FGF ligand trap could help develop more effective cancer therapies, potentially preventing the emergence of drug-resistant relapses.

References

Rajendran P, Li F, Shanmugam M, Vali S, Abbasi T, Kapoor S . Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol. 2011; 227(5):2184-95. DOI: 10.1002/jcp.22954. View

Szymczyk J, Sluzalska K, Materla I, Opalinski L, Otlewski J, Zakrzewska M . FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers (Basel). 2021; 13(22). PMC: 8616288. DOI: 10.3390/cancers13225796. View

Weronika Swiderska K, Szlachcic A, Opalinski L, Zakrzewska M, Otlewski J . FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1. Int J Mol Sci. 2018; 19(7). PMC: 6073801. DOI: 10.3390/ijms19072098. View

Lassman A, Sepulveda-Sanchez J, Cloughesy T, Gil-Gil M, Puduvalli V, Raizer J . Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022; 28(11):2270-2277. PMC: 9167702. DOI: 10.1158/1078-0432.CCR-21-2664. View

Tolcher A, Papadopoulos K, Patnaik A, Wilson K, Thayer S, Zanghi J . A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol. 2015; 27(3):526-32. DOI: 10.1093/annonc/mdv591. View

Banik K, Ranaware A, Deshpande V, Nalawade S, Padmavathi G, Bordoloi D . Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. Pharmacol Res. 2019; 144:192-209. DOI: 10.1016/j.phrs.2019.04.004. View

Ornitz D, Itoh N . New developments in the biology of fibroblast growth factors. WIREs Mech Dis. 2022; 14(4):e1549. PMC: 10115509. DOI: 10.1002/wsbm.1549. View

Szymczyk J, Sochacka M, Chudy P, Opalinski L, Otlewski J, Zakrzewska M . FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT two independent mechanisms. Front Oncol. 2022; 12:1011762. PMC: 9582358. DOI: 10.3389/fonc.2022.1011762. View

Pozniak M, Porebska N, Krzyscik M, Sokolowska-Wedzina A, Jastrzebski K, Sochacka M . The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells. Mol Med. 2021; 27(1):46. PMC: 8103757. DOI: 10.1186/s10020-021-00306-2. View

10.

Dai Z, Huang Y, Sadee W . Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem. 2004; 4(13):1347-56. DOI: 10.2174/1568026043387746. View

11.

Yosaatmadja Y, Patterson A, Smaill J, Squire C . The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition. Acta Crystallogr D Biol Crystallogr. 2015; 71(Pt 3):525-33. DOI: 10.1107/S1399004714027539. View

12.

Pearson H, Iida M, Orbuch R, McDaniel N, Nickel K, Kimple R . Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. Mol Cancer Ther. 2017; 17(1):204-214. PMC: 5752575. DOI: 10.1158/1535-7163.MCT-17-0384. View

13.

Szymczyk J, Czyrek A, Otlewski J, Zakrzewska M . FGF1 Protects MCF-7 Cells against Taltobulin through Both the MEKs/ERKs and PI3K/AKT Signaling Pathway. Biomedicines. 2023; 11(7). PMC: 10376943. DOI: 10.3390/biomedicines11071856. View

14.

Cha H, Choi J, Park I, Kim C, An S, Kim T . Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells. Int J Oncol. 2017; 50(4):1279-1288. DOI: 10.3892/ijo.2017.3913. View

15.

Javle M, Lowery M, Shroff R, Weiss K, Springfeld C, Borad M . Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2017; 36(3):276-282. PMC: 6075847. DOI: 10.1200/JCO.2017.75.5009. View

16.

Pan J, Lee Y, Zhang Q, Xiong D, Wan T, Wang Y . Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway. Cancer Prev Res (Phila). 2016; 10(2):133-141. PMC: 6005650. DOI: 10.1158/1940-6207.CAPR-16-0129. View

17.

Shee K, Yang W, Hinds J, Hampsch R, Varn F, Traphagen N . Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018; 215(3):895-910. PMC: 5839765. DOI: 10.1084/jem.20171818. View

18.

Song J, Anandharaj A, Upadhyaya P, Kirtane A, Kim J, Hong K . Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors. Oncotarget. 2016; 7(36):57752-57769. PMC: 5295387. DOI: 10.18632/oncotarget.10759. View

19.

Wang Z, Li X, Wang D, Zou Y, Qu X, He C . Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles. Acta Biomater. 2017; 62:144-156. DOI: 10.1016/j.actbio.2017.08.027. View

20.

Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C . Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011; 54(20):7066-83. DOI: 10.1021/jm2006222. View